Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | LTK | P29376 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926130 | 0.68 | ADORA2A (0.31) | — | |
| SCHEMBL30060196 | 0.66 | CCR1 (0.44) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL422300 | 0.66 | CCR1 (0.44) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL71510 | 0.64 | — | — | |
| SCHEMBL2010154 | 0.63 | — | — | |
| SCHEMBL21295836 | 0.61 | KDM4E (0.33) | — | |
| SCHEMBL14438012 | 0.61 | L3MBTL1 (0.34) | NTRK1LTKTYRO3NTRK2CLK4 | |
| SCHEMBL14309739 | 0.61 | CYP1A2 (0.44) | NTRK1NTRK2CLK4MAPK1HSD17B10 | |
| SCHEMBL7954685 | 0.60 | CYP1A2 (0.48) | L3MBTL1 | |
| SCHEMBL315820 | 0.60 | TP53 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060063818-A1 | Hydantoin derivatives and deren verwendung als tace inhibitoren | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060019994-A1 | I-sulphonlyl piperidine derivatives | ASTRAZENECA AB (SE) | 2006-01-26 | — | — | US | disclosed |
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ASTAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1539706-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1539740-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1534281-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | Astrazeneca AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004024698-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024715-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004006925-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256176-A1 | Sulphonamide derivatives and their use as tace inhibitors | ADAM10, ADAM17, TNF | NTRK1 2872/4885LTK 2938/4885TYRO3 3177/4885 |
| US-20060019994-A1 | I-sulphonlyl piperidine derivatives | MMP1, TPSAB1, CASP1 | NTRK1 4486/4885LTK 1783/4885TYRO3 3407/4885 |
| US-20060063818-A1 | Hydantoin derivatives and deren verwendung als tace inhibitoren | HPN, ADAM17, ADAM33 | NTRK1 3194/4885LTK 3759/4885TYRO3 4461/4885 |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ADAM10, ADAM9, CTRL | NTRK1 4084/4885LTK 3763/4885TYRO3 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.